DS03 - Stimuler le renouveau industriel

Shape-controlled nanomaterials: the new therapeutic approach for mucosal routes – Shape

Submission summary

Mucosal routes are the preferred sites for drug administration in comparison with invasive parenteral routes. However, the design of drug carriers able to avoid dilution with physiological fluids and rapid mucus clearance still represents an unmet challenge. Nanoparticles (NPs) coated with mucoadhesive polymers have shown their ability to address some aspects of these problems, mainly due to their small size and mucoadhesive surface. However, while NP size and surface properties have been extensively studied, there is a lack of investigations on shape dependency of NP mucoadhesive behaviours.
The original strategy proposed here is to consider the shape of NPs as a new parameter to make them rapidly reach mucus avoiding dilution with physiological fluids and accumulate at high concentrations close to the mucosal epithelium. This program aims to understand the impact of NP morphology on: (i) their diffusion in biological fluids, (ii) diffusion through mucus, (iii) interaction with mucus constituents, mainly mucins, (iv) cellular uptake and passage through mucosal membranes.
The principal investigator (PI) and her team provided robust proof of concepts: (i) They have recently developed two technological platforms offering unlimited possibilities for designing non-spherical polymer NPs with simultaneous control of shape and size, and versatile surface modification. (ii) They showed that elongated and flattened NPs exhibited four-times faster mobility in water than spherical NPs.
The strength of this multidisciplinary and ambitious program is to combine fundamental investigations with applied research in areas of importance to healthcare using unconventional nanotechnology approach. This project addresses a relevant question and has a clear stepwise workplan. The chances of success remain high thanks to the skills of the PI acquired during her ten-year carrier and highly specific intellectual support of her team members. This programme will be conducted in the laboratory “Institut Galien Paris Sud”, UMR CNRS 8612, which represents one of the most important research structure in the field of pharmaceutical nanotechnology in France and in Europe.

Project coordination

Kawthar BOUCHEMAL (Institut Galien Paris Sud)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

IGPS Institut Galien Paris Sud

Help of the ANR 176,870 euros
Beginning and duration of the scientific project: March 2018 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter